The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma

被引：0

作者：

Falchi, Lorenzo ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY 10065 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2024年 / 22卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：12 / 15

页数：4

共 18 条

[1] [Anonymous], 2018, Blinatumomab (Blincyto) prescribing information
[2] [Anonymous], 2022, Obinutuzumab (Gazyva) prescribing information.
[3] CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Bacac, Marina
Colombetti, Sara
Herter, Sylvia
Sam, Johannes
Perro, Mario
Chen, Stanford
Bianchi, Roberta
Richard, Marine
Schoenle, Anne
Nicolini, Valeria
Diggelmann, Sarah
Limani, Florian
Schlenker, Ramona
Husser, Tamara
Richter, Wolfgang
Bray-French, Katharine
Hinton, Heather
Giusti, Anna Maria
Freimoser-Grundschober, Anne
Lariviere, Laurent
Neumann, Christiane
Klein, Christian
Umana, Pablo
[J]. CLINICAL CANCER RESEARCH, 2018, 24 (19) : 4785 - 4797
[4] Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
Challa-Malladi, Madhavi
Lieu, Yen K.
Califano, Olivia
Holmes, Antony B.
Bhagat, Govind
Murty, Vundavalli V.
Dominguez-Sola, David
Pasqualucci, Laura
Dalla-Favera, Riccardo
[J]. CANCER CELL, 2011, 20 (06) : 728 - 740
[5] Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
Dickinson, Michael
Gritti, Giuseppe
Carlo-Stella, Carmelo
Walter, Harriet S.
Carlile, David
Getzmann, Nicole
Curdt, Samira
Harrop, Emma
Keelara, Abiraj
Korfi, Koorosh
Labatut, Remi
Michielin, Francesca
Mycroft, Sarah Louise
Moore, Tom
Nutbrown, Robert
Palldino, Giuseppe
Whayman, Matt
Sam, Johannes
Weisser, Martin
Lechner, Katharina E.
Morschhauser, Franck
Hutchings, Martin
[J]. BLOOD, 2022, 140 : 3818 - 3820
[6] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, Michael J.
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Dixon, Mark
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
Trney, Marek
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24) : 2220 - 2231
[7] DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Engelberts, Patrick J.
Hiemstra, Ida H.
de Jong, Bart
Schuurhuis, Danita H.
Meesters, Joyce
Hernandez, Irati Beltran
Oostindie, Simone C.
Neijssen, Joost
van den Brink, Edward N.
Horbach, G. Jean
Verploegen, Sandra
Labrijn, Aran F.
Salcedo, Theodora
Schuurman, Janine
Parren, Paul W. H., I
Breij, Esther C. W.
[J]. EBIOMEDICINE, 2020, 52
[8] Falchi L., 2023, Blood, V142, P858
[9] Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
Falchi, Lorenzo
Vardhana, Santosha A.
Salles, Gilles A.
[J]. BLOOD, 2023, 141 (05) : 467 - 480
[10] Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Hutchings, Martin
Carlo-Stella, Carmelo
Morschhauser, Franck
Falchi, Lorenzo
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Baumlin, Pauline
Mulvihill, Estefania
Relf, James
Xie, Yuying
Kaufman, Derrick
Lundberg, Linda
Dickinson, Michael
[J]. BLOOD, 2023, 142

← 1 2 →